NEO · Neogenomics Inc
$16.66
+0.76 (+4.75%)
At close · Aug 19
Market Cap
$2.10B
Shares
130.21M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.66
Open$16.20
Day$16.08–16.70
52W close$6.10–16.66
Avg vol 30d2.6M
Short int15.4M · 11.8% float · 4.2d
Short vol54%
Last earningsJul 28, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 27, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 28, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+48%
above
Price vs 50-day avg
+17%
above
RSI (14)
63
neutral
MACD trend
Negative
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+19%
trailing
6-month return
+64%
trailing
YTD return
+42%
this year
Relative strength
+52%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +59 funds added
Insider flow
Distributing
Net -$321.4K over 90 days · 100% sells
Short interest
Rising
11.84% of float · ▲ +12.0% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
267 holders — mid 3-yr range
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
43%
contracting
EPS growth
−300%
Y/Y
Free cash flow
$-21.8M
Balance sheet
$182.2M
net debt
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−46%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 28, 2026
Consolidated revenue
· Updated FY 2026 Guidance
$802M – $806M
Net loss
· Updated FY 2026 Guidance
$-42M – $-34M
Adjusted EBITDA
· Updated FY 2026 Guidance
$56M – $58M
Prior guidance
period ended
· from the 8-K filed Jan 12, 2026
Total revenue
· fourth quarter of 2025
$190M
Total revenue
· full-year 2025
$727M
Guided vs delivered
· last 3 settled
Revenues
full year 2024
guided $650M – $660M
$660.57M
Beat +0.8%
Revenue
Q1 '24
guided $148M – $151M
$156.24M
Beat +4.5%
Total revenue
for the year
guided $585M – $592M
$591.64M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+48%
Bullish
Price vs 50-day avg
+17%
Bullish
RSI (14)
63
Neutral
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $11 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +59 funds added
Insider flow
Distributing
Net -$321.4K over 90 days · 100% sells
Short interest
Rising
11.84% of float · ▲ +12.0% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
267 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6
Now $17 · 100%
Range high $17
vs 200-day avg +48%
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $14M | Q2 2026 | — |
|
|
|||
| Adjusted Gross Profit Margin non-GAAP | 48% | Q2 2026 | — |
|
|
|||
| Adjusted Net Income non-GAAP | $7M | Q2 2026 | — |
| Average revenue/test | $505 | Six Months Ended June 30 | — |
|
|
|||
| Number of tests performed | 709,177 | Six Months Ended June 30 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NEO
this stock
Neogenomics Inc
|
$2.10B | +41.6% | +10.1% | — | 11.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.80B | +5.9% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -7.6% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$45.29B | +41.9% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -16.9% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NEO | +1.4% | +18.9% | +63.8% | +8.9% | +41.6% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +1.9% | +16.0% | +52.2% | +6.0% | +28.8% |
Key facts
CIK
1077183
CUSIP
64049M209
13F (30d)
241 filings
236 filers
Visit website
Investor relations